Li, Zhenyu

Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma

Wang, Y., Cao, J., Gu, W., Shi, M., Lan, J., Yan, Z., Jin, L., Xia, J., Ma, S., Liu, Y., et al. (2022) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 132

Anti–G Protein–Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial

Xia, J., Li, H., Yan, Z., Zhou, D., Wang, Y., Qi, Y., Cao, J., Li, D., Cheng, H., Sang, W., et al. (2023) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 94

CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed/refractory multiple myeloma: Updated results of phase 1b/2 study (FUMANBA-1).

Li, C., Wang, D., Song, Y., Huang, H., Li, J., Chen, B., Liu, J., Dong, Y., Hu, K., Liu, P., et al. (2023) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 28

Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study

Dai, H., Xu, S., Han, J., Li, Z., Cao, J., Hu, T., Li, H., Wei, J., Dou, X., Zhou, F., et al. (2021) · Journal of Affective Disorders

Cancer survivorship and careCAR-T cell therapy research

Cited by 16

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting

Xia, J., Li, Z., & Xu, K. (2023) · Journal of Hematology & Oncology

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 13